ClinicalTrials.gov record
Recruiting No phase listed Observational

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

ClinicalTrials.gov ID: NCT04165798

Public ClinicalTrials.gov record NCT04165798. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 30, 2026, 9:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

KEYMAKER-U01 Master Study: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants With Non-small Cell Lung Cancer (NSCLC)

Study identification

NCT ID
NCT04165798
Recruitment status
Recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
1,065 participants

Conditions and interventions

Interventions

  • Blood Sample Collection Procedure
  • Tumor Imaging Diagnostic Test
  • Tumor Tissue Collection Procedure

Procedure · Diagnostic Test

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 18, 2019
Primary completion
Feb 12, 2032
Completion
Feb 12, 2032
Last update posted
Apr 16, 2026

2019 – 2032

United States locations

U.S. sites
18
U.S. states
15
U.S. cities
17
Facility City State ZIP Site status
Banner MD Anderson Cancer Center ( Site 0001) Gilbert Arizona 85234 Completed
City of Hope ( Site 0014) Duarte California 91010 Completed
UCSF Medical Center at Mission Bay ( Site 0007) San Francisco California 94158 Completed
Georgetown University ( Site 0036) Washington D.C. District of Columbia 20007 Completed
University of Kentucky Markey Cancer Center ( Site 0019) Lexington Kentucky 40536-0293 Completed
MedStar Franklin Square Medical Center ( Site 0033) Baltimore Maryland 21237 Completed
Massachusetts General Hospital ( Site 0003) Boston Massachusetts 02114 Completed
Dana Farber Cancer Institute ( Site 0002) Boston Massachusetts 02215 Completed
Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031) Omaha Nebraska 68130 Completed
Dartmouth Hitchcock Medical Center ( Site 0016) Lebanon New Hampshire 03766 Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037) Hackensack New Jersey 07601 Completed
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0034) New York New York 10016 Completed
Sanford Fargo Medical Center ( Site 0039) Fargo North Dakota 58102 Recruiting
Cleveland Clinic Main ( Site 0006) Cleveland Ohio 44195 Completed
Ohio State University Comprehensive Cancer Center ( Site 0015) Columbus Ohio 43210 Recruiting
Abramson Cancer Center of the University of Pennsylvania ( Site 0010) Philadelphia Pennsylvania 19104 Recruiting
Sanford Cancer Center ( Site 0038) Sioux Falls South Dakota 57104 Recruiting
The University of Texas MD Anderson Cancer Center ( Site 0009) Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04165798, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 16, 2026 · Synced Apr 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04165798 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →